Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio  >>  Phase 1
Welcome,         Profile    Billing    Logout  

12 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
NCT04385849: Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Active, not recruiting
1b
1
US
N-803, Saline
ImmunityBio, Inc.
COVID-19
07/22
07/22
NCT05981131: Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1b
6
US
N803 plus Bacillus Calmette-Guerin (BCG)
ImmunityBio, Inc.
Non Muscle Invasive Bladder Cancer
08/33
08/33
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Completed
1
14
US
Natural Killer (NK) Cells, ALT803, Cytokine
Brenda Cooper, MD
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma
06/21
02/23
NCT04290546: CIML NK Cell in Head & Neck Cancer

Recruiting
1
25
US
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, cytokine induced memory-like natural killer, Ipilimumab, CTLA-4 inhibitor, Cetuximab, EGFR inhibitor
Dana-Farber Cancer Institute, Altor BioScience, Bristol-Myers Squibb, Miltenyi Biomedicine GmbH
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
09/24
12/24
NCT06040918: Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Recruiting
1
10
US
N-803
ImmunityBio, Inc.
Healthy Subjects
06/24
06/24
NCT06318871: Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Not yet recruiting
1
5
US
Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, NK Cells, N-803, Interleukin-15, Nogapendekin alfa inbakicept, IL-15sa
Dana-Farber Cancer Institute, Kidney Cancer Association, ImmunityBio, Inc.
Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma
02/25
02/30
NCT04898543: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
50
US
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
ImmunityBio, Inc.
Metastatic Solid Tumor
06/24
12/24
NCT06321484: Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Not yet recruiting
1
18
US
Cytokine-Induced Memory-like Natural Killer Cells, CIML NK Cells, IL-15 Superagonist, N-803
Dana-Farber Cancer Institute, ImmunityBio, Inc.
Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent
11/26
10/31
NCT05618925: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Recruiting
1
20
US
N803, Anktiva, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab
ImmunityBio, Inc.
Non Hodgkin's Lymphoma Refractory/Relapsed
03/26
03/27
RV582, NCT05769569: Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

Withdrawn
1
35
RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGDM1400LS, N-803, Ad26.Mos4.HIV, MVA-BN-HIV, A244d11 gp120, ALFQ, Antiretroviral Therapy (ART)
Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program, Janssen Vaccines & Prevention B.V.
HIV-1-infection
07/25
07/25
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Recruiting
1
46
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
10/25
04/26
NCT05245292: 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Recruiting
1
36
US
3BNC117-LS, broadly neutralizing antibody, monoclonal antibody, 10-1074-LS, N803, IL-15 superagonist complex
Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID), Weill Medical College of Cornell University, University of Pennsylvania
Human Immunodeficiency Virus
12/25
12/25

Download Options